Use of ACE inhibitors and risk of community-acquired pneumonia
Abstract number: P834
Rafailidis P., Matthaiou D., Varbobitis I., Falagas M.
Objectives: The administration of angiotensin-converting enzyme (ACE) inhibitors has been suggested as an alternative strategy for lowering the risk of community-acquired pneumonia (CAP) in the elderly, especially in patients with neurological and cerebrovascular comorbidity.
Methods: We critically examined the relevant data from studies regarding the impact of ACE inhibitors in lowering the risk of CAP and/or mortality due to CAP in the elderly. We searched in PubMed, Cochrane database and references of initially retrieved articles, and in http://clinicaltrials.gov for ongoing trials.
Results: We identified 285 evaluable studies. Eleven studies met the inclusion criteria and were evaluated further, of which 6 were prospective studies, 2 randomised controlled trials, and 3 retrospective studies. All studies including patients of Asian origin demonstrated a statistical significance in favour of ACE inhibitors. This was not the case, though, for studies including patients of non-Asian origin.
Conclusion: The available data suggest that ACE inhibitors may contribute to the reduction of the risk of CAP. Nevertheless, the clinical data are scarce and mainly comprise of studies including patients of Asian origin. Since there seem to be differences regarding the genetic polymorphism of ACE among patients of different origin, future studies may need to incorporate relevant genetics data that may help clarify the role, if any, of ACE inhibitors in prevention of CAP.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|